Table 2 Prevalence of PIM drugs in long-term medication before start of cancer therapy (n = 136)
PIM drug (ATC code) | Number of patients | Proportion of patients with respective drug [%] |
Pantoprazole (A02BC02) | 42 | 30.9 |
Sitagliptin (A10BH01) | 8 | 5.9 |
Amiodarone (C01BD01) | 4 | 2.9 |
Verapamil (C08DA01) | 4 | 2.9 |
Rivaroxaban (B01AF01) | 3 | 2.2 |
Omeprazole (A02BC01) | 3 | 2.2 |
Amitriptyline (N06AA09) | 3 | 2.2 |
Sotalol (C07AA07) | 3 | 2.2 |
Diclofenac (M01AB05) | 2 | 1.5 |
Diltiazem (C08DB01) | 2 | 1.5 |
Methocarbamol (M03BA03) | 2 | 1.5 |
Metoclopramide (A03FA01) | 2 | 1.5 |
Pramipexole (N04BC05) | 2 | 1.5 |
Trospium (G04BD09) | 2 | 1.5 |
PIM drug class (ATC code level 2) | Number of drug prescriptions | |
Drugs for acid-related disorders (A02) | 47 | |
Drugs used in diabetes (A10) | 10 | |
Cardiac therapy (C01) | 8 | |
Calcium channel blockers (C08) | 7 | |
Psycholeptics (N05) | 6 | |
Psychoanaleptics (N06) | 5 | |
Antithrombotic agents (B01) | 4 | |
Anti-inflammatory and antirheumatic products (M01) | 3 | |
Beta blocking agents (C07) | 3 | |
Urologicals (G04) | 3 | |
Others | 11 | |